Literature DB >> 8492135

In vivo imaging of vesicular monoamine transporters in human brain using [11C]tetrabenazine and positron emission tomography.

M R Kilbourn1, J N DaSilva, K A Frey, R A Koeppe, D E Kuhl.   

Abstract

The pharmacokinetics of [11C]tetrabenazine, a high-affinity radioligand for the monoamine vesicular transporter, were determined in living human brain using in vivo imaging by positron emission tomography (PET). The radiotracer showed high brain uptake and rapid washout from all brain regions with relatively slower clearance from regions of highest concentrations of monoamine vesicular transporters (striatum), resulting in clear differential visualization of these structures at short intervals after injection (10-20 min). As the first human PET imaging study of a vesicular neurotransmitter transporter, these experiments demonstrate that external imaging of vesicular transporters forms a new and valuable approach to the in vivo quantification of monoaminergic neurons, with potential application to the in vivo study of neurodegenerative disorders such as Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8492135     DOI: 10.1111/j.1471-4159.1993.tb03521.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  13 in total

Review 1.  The role of neurotransporters in excitotoxicity, neuronal cell death, and other neurodegenerative processes.

Authors:  K P Lesch; A Heils; P Riederer
Journal:  J Mol Med (Berl)       Date:  1996-07       Impact factor: 4.599

2.  Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine.

Authors:  J L Tillerson; A D Cohen; J Philhower; G W Miller; M J Zigmond; T Schallert
Journal:  J Neurosci       Date:  2001-06-15       Impact factor: 6.167

Review 3.  Single-photon emission tomography imaging of dopamine terminal innervation: a potential clinical tool in Parkinson's disease.

Authors:  R B Innis
Journal:  Eur J Nucl Med       Date:  1994-01

Review 4.  Vesicular monoamine transporter 2: role as a novel target for drug development.

Authors:  Guangrong Zheng; Linda P Dwoskin; Peter A Crooks
Journal:  AAPS J       Date:  2006-11-10       Impact factor: 4.009

Review 5.  Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry.

Authors:  Kandatege Wimalasena
Journal:  Med Res Rev       Date:  2010-02-04       Impact factor: 12.944

6.  Distribution of vesicular monoamine transporter 2 protein in human brain: implications for brain imaging studies.

Authors:  Junchao Tong; Isabelle Boileau; Yoshiaki Furukawa; Li-Jan Chang; Alan A Wilson; Sylvain Houle; Stephen J Kish
Journal:  J Cereb Blood Flow Metab       Date:  2011-04-27       Impact factor: 6.200

Review 7.  Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons.

Authors:  Thomas S Guillot; Gary W Miller
Journal:  Mol Neurobiol       Date:  2009-03-04       Impact factor: 5.590

8.  A new VGLUT-specific potent inhibitor: pharmacophore of Brilliant Yellow.

Authors:  Yutaka Tamura; Kiyokazu Ogita; Tetsufumi Ueda
Journal:  Neurochem Res       Date:  2013-11-19       Impact factor: 3.996

9.  VMAT2-Deficient Mice Display Nigral and Extranigral Pathology and Motor and Nonmotor Symptoms of Parkinson's Disease.

Authors:  Tonya N Taylor; W Michael Caudle; Gary W Miller
Journal:  Parkinsons Dis       Date:  2011-02-21

10.  Brain imaging of vesicular monoamine transporter type 2 in healthy aging subjects by 18F-FP-(+)-DTBZ PET.

Authors:  Kun-Ju Lin; Yi-Hsin Weng; Chia-Ju Hsieh; Wey-Yil Lin; Shiaw-Pyng Wey; Mei-Ping Kung; Tzu-Chen Yen; Chin-Song Lu; Ing-Tsung Hsiao
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.